Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Sanofi Reports Positive Top-Line Results from First Phase 3 Study of Alemtuzumab (Lemtrada) in Multiple Sclerosis
Teriflunomide attenuates immunopathological changes in the dark agouti rat model of experimental autoimmune encephalomyelitis.
Understanding the Metabolic Consequences of Human Arylsulfatase A Deficiency through a Computational Systems Biology Study.
The "poison chair" treatment for multiple sclerosis.
Rituximab does not reset defective early B cell tolerance checkpoints.
Intrathecal interferon reduces exacerbations of multiple sclerosis.
The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group.
Health-related quality of life in multiple sclerosis: Direct and indirect effects of comorbidity.
Validation of the Brazilian version of the neurological fatigue index for multiple sclerosis.
195 How Well Do Neuroradiologists Predict the Side of Trigeminal Neuralgia?
Activity-Dependent and Experience-Driven Myelination Provide New Directions for the Management of Multiple Sclerosis.
The effectiveness of dimethyl fumarate monotherapy in the treatment of relapsing-remitting multiple sclerosis: a systematic review and meta-analysis.
Biogen Idec receives notification of PDUFA date extension
Comparison of Betaferon, Avonex, and Rebif in treatment of relapsing-remitting multiple sclerosis.
Genzyme’s once-daily, oral AUBAGIO® (teriflunomide) approved in Argentina for the treatment of relapsing multiple sclerosis
Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM study.
Phase IV, Rater-blinded, Randomized Study, Comparing the Effects of 250 mg of Betaseron With 20 mg of Copaxone in Patients With the Relapsing-remitting or Clinically Isolated Forms of Multiple Sclerosis Using 3 Tesla MRI With Triple-dose Gadolinium
Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis.
Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).
A Combination Trial of Copaxone plus Estriol in Relapsing Remitting Multiple Sclerosis
Interferon beta 1a anaphylaxis, a case report. Standardization of non-irritating concentration for allergy skin.
Long-term impact of interferon or Glatiramer acetate in multiple sclerosis: A systematic review and meta-analysis.
Genes associated with T helper 17 cell differentiation and function.
Long-term efficacy and safety of transanal irrigation in multiple sclerosis.
Interferon β-secreting mesenchymal stem cells combined with minocycline attenuate experimental autoimmune encephalomyelitis.

Pages